Covalon Receives FDA Approval for CovaClear Ag.MISSISSAUGA, Ontario -- Covalon Technologies Ltd. ("Covalon") (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:COV COV Composés Organiques Volatiles (French) COV Compuestos Orgánicos Volátiles (Spanish: Volatile Organic Compounds) COV Coefficient of Variation COV City of Villians (game) ) announces that it has received 510(k) approval from the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , for CovaClear Ag(TM), Collagen with silver Antimicrobial Gel Sheet Dressing. CovaClear Ag(TM) is the only hydrated hy·drat·ed adj. Chemically combined with water, especially existing in the form of a hydrate. Adj. 1. hydrated - containing combined water (especially water of crystallization as in a hydrate) hydrous collagen dressing with antimicrobial silver available in the market. E[acute accent]Dr. DiCosmo, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. stated that CovaClear Ag(TM) will be a unique product in the market place for a number of reasons: E[acute accent]- It is the only hydrated collagen-based silver ion-releasing dressing in the marketplace. A moist wound healing environment is known to improve the healing process and reduce scarring. E[acute accent]- It contains silver ion which is a broad spectrum antiseptic that allows the dressing to be an effective antimicrobial barrier. E[acute accent]- The dressing is transparent and allows clinicians to monitor high risk wounds without having to remove the dressing. E[acute accent]The introduction of CovaClear Ag(TM) is an expansion of Covalon's wound dressing and tissue repair product offerings. Covalon looks forward to offering this dressing through a number of distributors in the wound care market on a non-exclusive basis. E[acute accent]According to the 2000 Clinica Reports "New Developments in Wound Care", the wound care market, world wide, exceeds $15 Billion US per year. CovaClear Ag(TM) hydrated collagen antimicrobial wound dressings are indicated for the management of full and partial thickness wounds. The total US market for moist dressings (hydrocolloids / hydrogels) exceeds $500 million per year. E[acute accent]Covalon Technologies Ltd. is a company with advanced medical products that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility biocompatibility the quality of not having toxic or injurious effects on biological systems. biocompatibility 1. The extent to which a foreign, usually implanted, material elicits an immune or other response in a recipient 2. , and microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. attachment. E[acute accent]The TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release. E[acute accent]Covalon Technologies Ltd. (TSX VENTURE:COV) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion